<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159830">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01997294</url>
  </required_header>
  <id_info>
    <org_study_id>RJH20130115</org_study_id>
    <secondary_id>2011BAI11B05</secondary_id>
    <nct_id>NCT01997294</nct_id>
  </id_info>
  <brief_title>Sequential Therapy of Atorvastatin Improve Outcomes of ST-elevated Acute Myocardial Infarction</brief_title>
  <official_title>Sequential Therapy of Atorvastatin Improving Tissue Reperfusion and Clinical Outcomes of ST-elevated Acute Myocardial Infarction Study（The STRAIT Study）</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhang Qi, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <authority>China: Ministry of Science and Technology</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Statins have been approved to benefit patients underwent percutaneous coronary intervention
      (PCI). The current study is designed to evaluate the effectiveness and safety of Sequential
      Therapy of Atorvastatin in patients with ST-elevated myocardial infarction and receive PCI
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Major Adverse Events (MACE) Occourance Rate</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cardiac Death (CD)
Non-fatal re-inarction (CK-MB, cTNI or cTNT elevation again and over 3 times higher than up normal limit accompanied with syptoms or EKG indication)
revascularization driven by syptoms (CABG or re-PCI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoints</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>TMP and TIMI grade chage after stents implantation; EKG ST reduction
MACE ( same definition as primary endpoints)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safty Endpoints</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Impairment of liver and kidney function
Other adverse events related to statin use</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>sequential therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>80mg atorvastatin before primary PCI (PPCI) followed by 40mg/d for 7 days after PPCI followed by 20mg/d for 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Therapy of atorvastatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20mg/d before and after PPCI for 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequential therapy of atorvastatin</intervention_name>
    <description>80mg atorvastatin before PPCI and 40mg/d for 7 days after PPCI</description>
    <arm_group_label>sequential therapy group</arm_group_label>
    <arm_group_label>Usual Therapy of atorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sighed informed consent

          -  Diagnosised as acute myocardial infarction

          -  Time frame less than 12 hours since the occurance of chest pain

          -  Aggred to receive sirolimus-eluted coronary stents

          -  Patients willing to accepte follow-up

        Exclusion Criteria:

          -  Allegy to statins or with a history against statin therapy

          -  Allegy to any products that will be used during PPCI

          -  Disagreed to receive PPCI and other related therapy

          -  Existing sever liver dysfuntion that statins can not be used according to the
             guildlines

          -  Sever kidney dysfunction (creatinine &gt;3mg/dl or eGFR&lt;30ml/min)

          -  Sever left ventricular dysfunction (Killip grade 3)

          -  Patients are currently taking medicine that may influence the use of statin

          -  Patients with a history of alcohol abuse or durg abuse

          -  Woman during pregnancy or lactation

          -  Patients who has attended other clinical trials

          -  Patients who has received PCI or CABG previously

          -  Patients who can not agree to accept study protocol

          -  Other conditions that may not sutible for the current study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weifeng Shen, MD. PhD.</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Cardiovascular Diseases, School of Medicine, Shanghai Jiao Tong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruiyan Zhang, MD.</last_name>
    <phone>+8664370045</phone>
    <phone_ext>665215</phone_ext>
    <email>Zhangruiyan@263.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhengbin Zhu, MD.</last_name>
    <phone>+8664370045</phone>
    <phone_ext>665380</phone_ext>
    <email>Gemini198306@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ruijin Hospital, Dept. of Cardiology</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Chen, MD</last_name>
      <phone>+862164370045</phone>
      <phone_ext>665380</phone_ext>
      <email>rjchenxin@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Ruiyan Zhang, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://cdc.rocksh.cn/</url>
    <description>website provided by CRO</description>
  </link>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 27, 2013</lastchanged_date>
  <firstreceived_date>November 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University</investigator_affiliation>
    <investigator_full_name>Zhang Qi, MD</investigator_full_name>
    <investigator_title>Visa Chief of Department of Cardiology</investigator_title>
  </responsible_party>
  <keyword>sequential therapy</keyword>
  <keyword>atorvastatin</keyword>
  <keyword>acute myocardial infarction</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
